EU signs preliminary deal with Novavax for up to 200 million Covid vaccine doses

The European Commission has approved a supply contract with US firm Novavax to buy up to 200 million doses of Covid-19 vaccine.

The European Commission has approved its seventh Advanced Purchase Agreement (APA) with US pharmaceutical company Novavax to ensure access to 200 million doses of its potential Covid-19 vaccine in Q4 of 2021 and in 2022. As variants are spreading, we need to stay vigilant.We approved a new contract with @Novavax for 200 million doses of its vaccine, which is already being tested successfully against variants.With our broad vaccine portfolio we protect Europeans and help vaccinate the world. pic.twitter.com/3IQ2692CAz Under the contract, member states will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for 100 million additional doses over the course of 2021, 2022, and 2023, once reviewed and approved by the European Medicines Agency (EMA) as safe and effective, the Commission said in a statement.